Table 3.
IC50 and Combination Index analysis of combination therapies on T24
| IC50 (95% CI,nM) | Effect (IC50 + Palbociclib 1000 nM) | Combination Index | |
|---|---|---|---|
| Axitinib | 919.1 (754.8–1119) | 0.63 | 0.67 |
| Erdafitinib | 3752 (3296–4271) | 0.79 | 0.43 |
| NVP-BEZ235 | 9.12 (6.755–12.31) | 0.67 | 0.33 |
| CI-1040 | 1661 (1225–2254) | 0.87 | 0.2 |
| MK2206 | 1260 (407.6–3897) | 0.55 | 0.44 |
| PIK90 | 1581 (908.4–2753) | 0.74 | 0.16 |
| Everolimus | 3.501 (1.605–7.637) | 0.65 | 0.15 |
| Roscovitine | 4815 (3094–7492) | 0.81 | 0.72 |
| SH-4-54 | 2324 (2129–2537) | 0.57 | 2.93 |
| Stattic | 2384 (2015–2820) | 0.53 | 0.88 |
| Ruxolitinib | 21221 (18381–24500) | 0.54 | 3.85 |